Patents by Inventor Jianwen Feng

Jianwen Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20250122159
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 22, 2024
    Publication date: April 17, 2025
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20250034119
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: June 14, 2024
    Publication date: January 30, 2025
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • Kinase Inhibitors and Uses Thereof
    Publication number: 20250011338
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: September 18, 2024
    Publication date: January 9, 2025
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 12180211
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: December 31, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cheng Hu, Maksim Osipov, Zachary K. Sweeney, Javier de Vicente Fidalgo, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 12139478
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 12, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney
  • Kinase inhibitors and uses thereof
    Patent number: 12129263
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 29, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 12091392
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: September 17, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara
  • Compounds, Compositions and Methods
    Publication number: 20240150376
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: August 10, 2023
    Publication date: May 9, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20240140919
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 2, 2024
    Inventors: Robert A. Craig II, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Tottumkara
  • Compounds, compositions and methods
    Patent number: 11958840
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 11851433
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Substituted pyrimidines as LRKK2 inhibitors
    Patent number: 11840529
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 12, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions, and methods
    Patent number: 11834439
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: December 5, 2023
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20230250072
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230227436
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 20, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230114472
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 23, 2022
    Publication date: April 13, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Compounds, compositions, and methods
    Patent number: 11591316
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • Compounds, Compositions and Methods
    Publication number: 20230043400
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 9, 2023
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Publication number: 20220411433
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 29, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney